PriceTargets.com logo

Silk Road Medical - SILK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $52.83
  • Forecasted Upside: 38.71%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$38.09 As of 03/24/2023 01:00 AM ET
▼ -0.57 (-1.47%)

This chart shows the closing price for SILK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Silk Road Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SILK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SILK

Analyst Price Target is $52.83
▲ +38.71% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Silk Road Medical in the last 3 months. The average price target is $52.83, with a high forecast of $70.00 and a low forecast of $43.00. The average price target represents a 38.71% upside from the last price of $38.09.

This chart shows the closing price for SILK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Silk Road Medical. This rating has held steady since March 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/10/2023CitigroupUpgradeSell ➝ Neutral$50.00Low
2/7/2023Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
1/9/2023ArgusBoost Target$60.00 ➝ $70.00Low
11/22/2022Bank of AmericaInitiated CoverageBuy$60.00Low
11/15/2022CitigroupBoost Target$38.00Low
10/5/2022CitigroupBoost Target$33.00 ➝ $34.00Low
7/18/2022Stifel NicolausLower Target$55.00 ➝ $46.00Low
7/11/2022CitigroupDowngradeNeutral ➝ Sell$33.00N/A
5/17/2022CitigroupLower Target$44.00 ➝ $33.00N/A
4/5/2022Wolfe ResearchInitiated CoverageOutperform$48.00Low
4/4/2022Piper SandlerBoost TargetNeutral$38.00 ➝ $43.00Medium
2/25/2022CitigroupLower TargetNeutral$45.00 ➝ $37.00High
2/25/2022Piper SandlerLower Target$48.00 ➝ $38.00High
1/3/2022Piper SandlerLower Target$55.00 ➝ $48.00Low
11/22/2021ArgusLower TargetBuy$70.00 ➝ $60.00High
11/19/2021CitigroupUpgradeSell ➝ Neutral$50.00Medium
11/10/2021SVB LeerinkLower TargetOutperform$75.00 ➝ $66.00High
10/1/2021CitigroupDowngradeNeutral ➝ Sell$50.00Medium
7/30/2021Piper SandlerLower TargetNeutral$58.00 ➝ $55.00High
7/20/2021SVB LeerinkReiterated RatingOutperformHigh
3/2/2021CitigroupLower Target$64.00 ➝ $59.00High
11/11/2020Piper SandlerBoost TargetNeutral$54.00 ➝ $58.00Medium
10/12/2020SVB LeerinkBoost TargetOutperform$60.00 ➝ $75.00Low
10/1/2020CitigroupDowngradeBuy ➝ Neutral$58.00 ➝ $71.00High
8/21/2020Piper SandlerInitiated CoverageNeutral$54.00High
8/6/2020Stifel NicolausBoost TargetBuy$47.00 ➝ $55.00High
8/6/2020SVB LeerinkBoost TargetOutperform$51.00 ➝ $60.00Medium
8/6/2020CitigroupBoost TargetBuy$50.00 ➝ $58.00Medium
7/9/2020SVB LeerinkInitiated CoverageOutperform$51.00High
7/1/2020Stifel NicolausReiterated RatingBuy$47.00Low
5/27/2020CitigroupInitiated CoverageBuy$50.00High
5/1/2020Stifel NicolausBoost TargetBuy$37.00 ➝ $47.00Low
2/27/2020Stifel NicolausBoost TargetBuy$49.00 ➝ $51.00High
8/20/2019ArgusInitiated CoverageBuy$52.00 ➝ $52.00Low
4/29/2019Bank of AmericaInitiated CoverageNeutral ➝ Neutral$43.00Medium
4/29/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$45.00Low
4/29/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$44.00Low
4/29/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$40.01Low
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
10/27/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2022
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 8 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 8 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Silk Road Medical logo
Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.
Read More

Today's Range

Now: $38.09
Low: $37.03
High: $38.85

50 Day Range

MA: $49.64
Low: $38.09
High: $57.79

52 Week Range

Now: $38.09
Low: $27.30
High: $58.04

Volume

786,784 shs

Average Volume

770,419 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Silk Road Medical?

The following sell-side analysts have issued research reports on Silk Road Medical in the last year: Argus, Bank of America Co., Citigroup Inc., Piper Sandler, Stifel Nicolaus, and Wolfe Research.
View the latest analyst ratings for SILK.

What is the current price target for Silk Road Medical?

6 Wall Street analysts have set twelve-month price targets for Silk Road Medical in the last year. Their average twelve-month price target is $52.83, suggesting a possible upside of 38.7%. Argus has the highest price target set, predicting SILK will reach $70.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $43.00 for Silk Road Medical in the next year.
View the latest price targets for SILK.

What is the current consensus analyst rating for Silk Road Medical?

Silk Road Medical currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SILK, but not buy more shares or sell existing shares.
View the latest ratings for SILK.

What other companies compete with Silk Road Medical?

Other companies that are similar to Silk Road Medical include Beauty Health, Paragon 28, Embecta, Treace Medical Concepts and Alphatec. Learn More about companies similar to Silk Road Medical.

How do I contact Silk Road Medical's investor relations team?

Silk Road Medical's physical mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company's listed phone number is (408) 720-9002 and its investor relations email address is [email protected] The official website for Silk Road Medical is www.silkroadmed.com. Learn More about contacing Silk Road Medical investor relations.